Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Neurocrine BiosciencesSTU:NB3 -0.41%90 Cyclically Adjusted PB Ratio is 10.01 as of Aug. 05, 2026, which is 38% below its 10-year median of 16.02. GuruFocus rates STU:NB3 with a GF Score™ of 90/100 and a GF Value™ of €169.44 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 737 Drug Manufacturers companies, Neurocrine Biosciences ranks worse than 93.22% on this metric.
The historical rank and industry rank for Neurocrine Biosciences's Cyclically Adjusted PB Ratio or its related term are showing as below:
STU:NB3'
s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 7.19 Med: 16.02 Max: 47.47
Current: 10.12
During the past years, Neurocrine Biosciences's highest Cyclically Adjusted PB Ratio was 47.47. The lowest was 7.19. And the median was 16.02.
STU:NB3's Cyclically Adjusted PB Ratio is ranked worse than 93.22% of 737
companies
in the Drug Manufacturers industry
Industry Median: 1.77
vs STU:NB3: 10.12
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.
Neurocrine Biosciences's adjusted book value per share data for the three months ended in Jun. 2026 was €31.556. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €14.39 for the trailing ten years ended in Jun. 2026.
Shiller PE for Stocks: The True Measure of Stock Valuation
Neurocrine Biosciences (STU:NB3) Cyclically Adjusted PB Ratio Explanation
Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.
Neurocrine Biosciences Cyclically Adjusted PB Ratio Related Terms
Neurocrine Biosciences Cyclically Adjusted PB Ratio Historical Data
* Premium members only.
The historical data trend for Neurocrine Biosciences's Cyclically Adjusted PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Neurocrine Biosciences Cyclically Adjusted PB Ratio Chart
STU:NB3 vs VTRS, UTHR, ELAN: Cyclically Adjusted PB Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Neurocrine Biosciences's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Neurocrine Biosciences Cyclically Adjusted PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Neurocrine Biosciences's Cyclically Adjusted PB Ratio distribution charts can be found below:
* The bar in red indicates where Neurocrine Biosciences's Cyclically Adjusted PB Ratio falls into.
Neurocrine Biosciences Cyclically Adjusted PB Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PB Ratio of 10.01 mean?
Neurocrine Biosciences (STU:NB3) has a Cyclically Adjusted PB Ratio of 10.01 as of Aug. 05, 2026. Cyclically Adjusted PB Ratio is the ratio of share price to a company's inflation-adjusted book value per share over a 10-year period. View historical data on Neurocrine Biosciences and its competitors. This is 38% below median its historical median of 16.02. Over the past decade, Neurocrine Biosciences' Cyclically Adjusted PB Ratio has ranged from 7.19 to 47.47. According to the industry distribution chart, Neurocrine Biosciences ranks #687 out of 737 companies in the Drug Manufacturers industry, placing it in the top 93.2%.
Is Neurocrine Biosciences' Cyclically Adjusted PB Ratio too high?
Neurocrine Biosciences' current Cyclically Adjusted PB Ratio of 10.01 is 38% below median its 10-year median of 16.02. Over the past 10 years, this metric has ranged from a low of 7.19 to a high of 47.47. The Drug Manufacturers industry median Cyclically Adjusted PB Ratio is 1.77. Neurocrine Biosciences' value of 10.01 is 465.5% above this industry median. Based on the distribution chart, Neurocrine Biosciences ranks #687 out of 737 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Neurocrine Biosciences has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Neurocrine Biosciences' Cyclically Adjusted PB Ratio compare to VTRS and UTHR?
According to the Drug Manufacturers industry distribution chart, Neurocrine Biosciences ranks #687 out of 737 companies for Cyclically Adjusted PB Ratio. This places Neurocrine Biosciences in the lower half of its industry. The industry median Cyclically Adjusted PB Ratio is 1.77. Neurocrine Biosciences' value of 10.01 is 465.5% above this benchmark. Historically, Neurocrine Biosciences' own Cyclically Adjusted PB Ratio has ranged from 7.19 to 47.47 over the past decade. While the company's 10-year median is 16.02 vs. the industry median of 1.77, Neurocrine Biosciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PB Ratio for a Drug Manufacturers company?
The median Cyclically Adjusted PB Ratio among Drug Manufacturers companies is 1.77, based on 737 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Neurocrine Biosciences's current Cyclically Adjusted PB Ratio of 10.01 is 465.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PB Ratio mean?
A high Cyclically Adjusted PB Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PB Ratio is the ratio of share price to a company's inflation-adjusted book value per share over a 10-year period. View historical data on Neurocrine Biosciences and its competitors. For the Drug Manufacturers industry, the median Cyclically Adjusted PB Ratio is 1.77 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Neurocrine Biosciences's current Cyclically Adjusted PB Ratio is 10.01, which is 38% below median its own 10-year median of 16.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neurocrine Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Neurocrine Biosciences (STU:NB3) is currently considered Modestly Undervalued. The stock's GF Value™ is €169.44, compared to a current price of €144.05 — trading 15% below its estimated fair value. The current Cyclically Adjusted PB Ratio is 10.01, which is 38% below median its 10-year median of 16.02 and 465.5% above the Drug Manufacturers industry median of 1.77. Neurocrine Biosciences' overall GF Score™ is 90/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PB Ratio calculated?
Cyclically Adjusted PB Ratio is calculated from a company's financial statements. For Neurocrine Biosciences (STU:NB3), the current Cyclically Adjusted PB Ratio is 10.01 as of Aug. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Neurocrine Biosciences (STU:NB3) Overvalued in 2026?
Based on GuruFocus' analysis, Neurocrine Biosciences stock appears to be undervalued.
The current stock price of €144.05 is trading 15% below its estimated GF Value™ of €169.44.
GuruFocus considers Neurocrine Biosciences to be Modestly Undervalued.
Key valuation signals for STU:NB3:
Cyclically Adjusted PB Ratio: 10.01 (38% below median its 10-year median of 16.02)
GF Value™: €169.44 vs. price of €144.05 (15% below fair value)
Industry Position: 465.5% above the Drug Manufacturers median (#687 of 737)
No single metric tells the full story. See the STU:NB3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
90GF Score
Get the complete analysis for STU:NB3
Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:NB3 has been successfully added to your 
